South Delhi Pharma, New Delhi, India
PERJETA (pertuzumab) Injection, for intravenous use
Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.
Facts of Perjeta (pertuzumab)
PERJETA (pertuzumab) Injection, for intravenous use
Initial U.S. Approval: 2012
Brand Name: Perjeta
Generic Name: pertuzumab
Manufacturer: F. Hoffmann La Roche ltd
Presentation: Vials
Strength: 420mg/14ml
Pack Size: 1’s
South Delhi Pharma can facilitate patients and physicians access to commercially approved medicines, “Perjeta (pertuzumab)” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Perjeta (pertuzumab) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
Contact Number:
M:+91-9891296838 / P:+91-11- 26532129
Email ID:
info@southdelhipharma.com
What Perjeta is?
PERJETA is a HER2/neu receptor antagonist indicated in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
What pertuzumab is?
Pertuzumab is administered as an intravenous infusion in combination with trastuzumab and docetaxel as a first line treatment for HER2-positive metastatic breast cancer. It is also used in the same combination as a neoadjuvant (given to reduce the size of a tumor, prior to surgery or radiation) for HER2-positive early breast cancer; as of 2016 this use had not been shown to increase survival.
